Why the study?
Does parenteral bretylium tosylate suppress resistant ventricular arrhythmias in patients with recurrent ventricular tachycardia or fibrillation?
Population
Patients with resistant ventricular arrhythmias, particularly recurrent, drug-resistant ventricular…
Design
Review
Authors
Loading...
May support consideration for refractory VT/VF; leaves open comparative efficacy versus modern agents.
Does parenteral bretylium tosylate suppress resistant ventricular arrhythmias in patients with recurrent ventricular tachycardia or fibrillation?
Bretylium tosylate is an effective parenteral agent for managing drug-resistant ventricular tachycardia and fibrillation due to its unique adrenergic and direct cardiac membrane effects.
Robert H. Heissenbuttel (1979) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: